Paris - Delayed Quote EUR
Nanobiotix S.A. (NANO.PA)
At close: October 18 at 5:35 PM GMT+2
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
30,058.0000
30,058.0000
--
10.0000
50.0000
--
Operating Expense
56,836.0000
56,836.0000
46,703.0000
52,588.0000
36,478.0000
--
Operating Income
-26,778.0000
-26,778.0000
-46,703.0000
-52,578.0000
-36,428.0000
--
Net Non Operating Interest Income Expense
-6,480.0000
-6,480.0000
-12,436.0000
-658.0000
4,440.0000
--
Other Income Expense
-6,322.0000
-6,322.0000
2,106.0000
6,238.0000
-1,593.0000
--
Pretax Income
-39,580.0000
-39,580.0000
-57,033.0000
-46,998.0000
-33,581.0000
--
Tax Provision
120.0000
120.0000
10.0000
5.0000
9.0000
--
Net Income Common Stockholders
-39,700.0000
-39,700.0000
-57,041.0000
-47,003.0000
-33,590.0000
--
Diluted NI Available to Com Stockholders
-39,700.0000
-39,700.0000
-57,041.0000
-47,003.0000
-33,590.0000
--
Basic EPS
-1.08
-1.08
-1.64
-1.35
-1.38
--
Diluted EPS
-1.08
-1.08
-1.64
-1.35
-1.38
--
Basic Average Shares
36,928.1610
36,759.2590
34,851.8680
34,733.4180
24,385.8270
--
Diluted Average Shares
36,928.1610
36,759.2590
34,851.8680
34,733.4180
24,385.8270
--
Total Operating Income as Reported
-26,779.0000
-26,779.0000
-46,702.0000
-52,579.0000
-36,428.0000
--
Rent Expense Supplemental
--
--
--
9,638.0000
6,482.0000
9,435.0000
Total Expenses
56,836.0000
56,836.0000
46,703.0000
52,588.0000
36,478.0000
--
Net Income from Continuing & Discontinued Operation
-39,700.0000
-39,700.0000
-57,041.0000
-47,003.0000
-33,590.0000
--
Normalized Income
-34,958.5000
-34,958.5000
-59,147.0000
-51,587.9300
-31,997.0000
--
Interest Income
1,217.0000
1,217.0000
256.0000
--
4,676.0000
--
Interest Expense
7,982.0000
7,982.0000
5,837.0000
671.0000
333.0000
--
Net Interest Income
-6,480.0000
-6,480.0000
-12,436.0000
-658.0000
4,440.0000
--
EBIT
-31,598.0000
-31,598.0000
-51,196.0000
-46,327.0000
-33,248.0000
--
EBITDA
-30,085.0000
-30,085.0000
-49,696.0000
-44,767.0000
-31,494.0000
--
Reconciled Depreciation
1,513.0000
1,513.0000
1,500.0000
1,560.0000
1,754.0000
--
Net Income from Continuing Operation Net Minority Interest
-39,700.0000
-39,700.0000
-57,041.0000
-47,003.0000
-33,590.0000
--
Total Unusual Items Excluding Goodwill
-6,322.0000
-6,322.0000
2,106.0000
6,238.0000
-1,593.0000
--
Total Unusual Items
-6,322.0000
-6,322.0000
2,106.0000
6,238.0000
-1,593.0000
--
Normalized EBITDA
-23,763.0000
-23,763.0000
-51,802.0000
-51,005.0000
-29,901.0000
--
Tax Rate for Calcs
0.0003
0.0003
--
0.0003
--
--
Tax Effect of Unusual Items
-1,580.5000
-1,580.5000
--
1,653.0700
--
--
12/31/2019 - 10/29/2012
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ALSEN.PA Sensorion SA
0.7300
0.00%
ALCLS.PA Cellectis S.A.
1.8360
+0.44%
IPH.PA Innate Pharma S.A.
1.8700
-1.27%
ALCOX.PA Nicox S.A.
0.2680
+1.32%
6IRA.BE IRLAB Therapeutics AB
1.0900
+5.83%
ADOC.PA Adocia SA
7.49
+21.00%
VICO.ST Vicore Pharma Holding AB (publ)
8.62
-6.00%
GNRO.PA GeNeuro SA
0.0828
+7.25%
AELIS.PA Aelis Farma SA
3.6000
-8.63%
KDEV.ST Karolinska Development AB (publ)
1.2760
+4.25%